A four-year follow-up published in the New England Journal of Medicine reports that an AAV8-mediated gene therapy for Crigler–Najjar syndrome maintains disease control and safe bilirubin levels through extended observation. The durability signal is clinically important for a condition where lifelong management is typically required and treatment goals depend on long-term metabolic stability. The extended period of monitoring also strengthens confidence that a one-time dosing approach can sustain benefit without late declines in biochemical markers. For the gene therapy field, the report supports continued investment in AAV capsids and dosing regimens designed for durable hepatic transgene expression.